Article

Duke spin-off firm wins FDA marketing approval

Research Triangle Park, NC-The FDA has approved marketing to begin for a new, non-invasive eye scanner developed by a company spun off from Duke University's biomedical engineering department.

Research Triangle Park, NC-The FDA has approved marketing to begin for a new, non-invasive eye scanner developed by a company spun off from Duke University's biomedical engineering department.

Bioptigen Inc.'s imaging system is designed to deliver microscale, three-dimensional images of the retina and other eye surfaces 50 times faster than other scanners. The spectral domain optical coherence tomography (SD-OCT) scanners can aid in the diagnosis of glaucoma and other diseases, according to the company.

Bioptigen also is developing other imaging systems for use inside or outside the body, as well as image-processing software. The company recently received two federal research grants for further developing SD-OCT technology and for another system to be used at the genetic level.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.